Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — BofA Merrill Lynch Global Healthcare Conference 2010
19 slides from Teva Pharmaceutical Industries's conference presentation, Sep 17, 2010
Slide 1: BofA Merrill Lynch Global Healthcare Conference
BofA Merrill Lynch Global Healthcare Conference Investor Dr. Gerard van Odijk Relations President and CEO, Teva Europe London, 17 September 2010 Investor Relations 1
Slide 2: Forward looking statements
Forward looking statements TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE OUR FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIF
Slide 3: Targets for 2015
Targets for 2015 Revenues $31 bn Net income $6.8 bn Net profitability 22% Investor Relations 3
Slide 4: Growth through market share: 2015 sales targets
Growth through market share 2015 sales 2009-2015 targets CAGR North America $15bn 9.5% Europe $9bn 18.6% International $7bn 23.2% Total $31bn 14.3% Investor Relations 4
Slide 5: Still room for growth in generics? - YES!
Still room for growth in generics? - YES! $135-150 bn in 2015 GROWTH GROWTH GROWTH GROWTH Increasing People living Healthcare $150bn of opportunities longer and reforms and brands going in emerging consuming cost saving off-patent generics more drugs initiatives in the next markets 5 years Investor
Slide 6: Growing demand for generics
Growing demand for generics Market outlook for global generic sales $135-150bn $150bn in brand value New products $80bn Emerging patent Developed generics expirations International countries markets Europe Current Future portfolio portfolio North America 2008 2015 Source: Exane BNP Paribas, IMS, Esp
Slide 7: Europe is an important growth engine
Europe is an important growth engine 2015 sales 2009-2015 Our European goal targets CAGR $bn 9.2 North $15bn 9.5% America R AG C % Europe $9bn 18.6% 8.6 1 3.3 International $7bn 23.2% Total $31bn 14.3% 9 15 ratiopharm acquisition – supports 2015 strategic goal Investor Relations 7
Slide 8: Ratiopharm: strategic fit and value creation
Ratiopharm: strategic fit and value creation Indisputable leadership, #1 in Europe #2 in Germany Balanced: countries, customers, products Strong operational platform Investor Relations 8
Slide 9: Becoming the European market leader
Becoming the European market leader 1 UK 1 Italy Strong platform for future growth 1 Spain 1 Netherlands 1 Hungary 2 Germany Strong #1 in 10 Top 3 in 7 pan- 2 Czech Republic European EU other EU markets markets footprint 3 France 3 Poland Investor Relations 9
Slide 10: The German generics market
The German generics market Generics market segments (value) - 2010 #1 market in Europe #2 market globally OTC 11% Hospital Old originals 6% Market size: ~€9.5bn* gross 30% Multiple segments Retail 53% Only part of the retail segment is subject to tenders * Retail, Hospital, OTC and old originals Inv
Slide 11: Strong international growth
Strong international growth Pharma market (CAGRs 2009-2015) CIS Eastern 14% Europe 10% Asia Japan 16% 3% Latin International America markets: 12% 2009: $241bn 2015: $473bn Source: 2009 – 2013 IMS Market Prognosis – Constant fx, Teva Investor Relations 11
Slide 12: Continued focus on high-priority markets
Continued focus on high-priority markets Priority 8 ~75% of growth growth markets countries Established growth markets 52 countries Investor Relations 12
Slide 13: The Teva advantages cross all models
The Teva advantages crosses all models Multiple generics models Teva's advantages Generics- • 1,250 generic molecules Gx (G-Gx) • Local market knowledge • Relationships: payers & buyers • Regulatory expertise Branded Gx Hospitals • Vertical integration (B-Gx) • Speed & agility • High quality product
Slide 14: Maintaining Teva's mix of generic/branded
Maintaining Teva’s mix of generic/branded $31bn ~30% $13.9bn Branded 30% ~70% Generics 70% 2009 2015 Investor Relations 14
Slide 15: Copaxone and MS competitive landscape
Copaxone® and MS competitive landscape No.1 MS therapy in the U.S. and globally Continued Continued solid growth: 13% QoQ performance Record U.S. share: 39.7% TRxs / 38.4% NRxs Copaxone SONG (low dose Copaxone) FDA action date: 01/01/11 improvements GALA – 3x / week 40 mg - began recruiting in Q2 20
Slide 16: Teva Branded - multifaceted approach & experience
Teva Branded - multifaceted approach & experience Investor Relations 16
Slide 17: Loaded innovation pipeline
Loaded innovation pipeline Copaxone® TV-1101 (OGX-011) (Phase III) Multiple Sclerosis Prostate Cancer 1st line Innovative Azilect® Laquinimod – Oral Multiple TV-1101 (OGX-011) (Phase III) Parkinson’s Sclerosis (Phase III) Prostate Cancer 2nd line StemEx® – Hemato- TV-1101 (OGX-011) QVAR® oncological
Slide 18: Teva 2010-2015: value creation
Teva 2010-2015: value creation Growth Sustainable, balanced business model High profitability Financial strength Investor Relations 18
Slide 19: Q&A
Q&A Investor Relations 19
Teva Pharmaceutical Industries — BofA Merrill Lynch Global Healthcare Conference 2010 on 6ix